Here’s the latest on RSV vaccines as of now.
-
FDA expanded approval for Moderna mResvia (mRNA-1345) to prevent RSV in adults 18–59 at increased risk for severe disease. This adds a younger high-risk group to the existing 60+ indication.[1]
-
Pfizer’s Abrysvo has also gained extended indications. In 2024 it was approved for adults 18–59 at high risk, broadening its use beyond the 60+ group and continuing to be indicated for pregnant individuals at 32–36 weeks to protect infants after birth.[2][7]
-
The ACIP (advisory committee) has discussed expanding recommendations for RSV vaccines to additional adult age ranges and risk groups, with ongoing consideration of prioritization and guidance for use in younger adults. Changes depend on ACIP votes and DHHS leadership updates.[10][1]
-
Since RSV vaccine approvals often accompany updates to pregnancy-related protection (to shield newborns) and to other age groups, check the latest CDC/ACIP summaries for current recommendations and any new safety signals.[5][1][10]
Illustrative example: If you’re a clinician or caregiver, you might see guidance like: adults 60+ or 18–59 with certain conditions may be eligible for Arexvy, Abrysvo, or mResvia depending on age and risk, with pregnant individuals continuing to use Abrysvo to protect newborns.[4][7][2]
Would you like a concise, up-to-date table of the approved vaccines, their current age/risk indications, and key study highlights? I can pull the latest official statements and format it for quick reference.[1][2][4]
Sources
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.
www.cidrap.umn.eduOn May 3, the U.S. Food and Drug Administration (FDA) approved Arexvy, a vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in individuals 60 years and older. Arexvy is the first vaccine for RSV approved for use in the U.S.
www.acc.orgFirst and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower respiratory tract disease caused by RSV Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused...
www.pfizer.comGSK said Friday the US Food and Drug Administration expanded the approved age indication of Arexvy to adults aged 18 to 49 at heightened risk of lower respiratory tract disease from the...
www.marketscreener.comFDA approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV.
www.fda.govFDA's approval is for use of the vaccine, called Abrysvo, at 32 to 36 weeks gestational age of pregnancy.
www.cidrap.umn.eduVote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes...
www.pfizer.com